2 Stocks to Benefit from Australia Reopening

2 Stocks to Benefit from Australia Reopening

5 Oct, 2021 | Stock Insight

This week we look at two stocks that are growing through strategic acquisition plans and are set to benefit from Australia’s imminent reopening and easing of restrictions. While they are both in very different industries, they have been performing well and we believe they are good companies to own heading into the reopening tailwinds.
The stocks in question are Healthia and People Infrastructure.

Healthia (HLA.ASX)

Healthia (HLA) logo

​Healthia is an integrated allied healthcare organisation that includes networks of optometry, podiatry, and physiotherapy clinics across Australia. The physio/podiatry industry is a fragmented one that has allowed Healthia to grow through an aggressive acquisition strategy, giving them a strong presence throughout Australia. Following their most recent acquisition of Back in Motion (BIM),  HLA is now positioned as the largest provider of physio services in Australia with 122 clinics.

Reopening Tailwind
Picture

Author: Ron Shamgar & Adam Wolf

Most of Healthia’s clinics have remained essential services, which saw them continue operations throughout lockdowns. The lockdowns would’ve caused many people to delay visits to a lot of Healthia’s clinics; we can see there being a huge backlog of people waiting for restrictions to ease to go to one of Healthia’s broad range of health services.

Acquisitions

As mentioned, HLA has been undertaking an aggressive acquisition strategy to grow the business. They have been rolling up clinics throughout Australia which have all been earnings accretive. Their most recent acquisition of BIM, for a consideration of $88m, was a transformative one. Simply, it gave HLA a presence in new markets; BIM had a presence in New Zealand and Western Australia. BIM will add 64 clinics to the group and generated $12.3m of EBITDA, increasing the group EBITDA by approximately 57%. The acquisition is earnings accretive and was bought for circa 7x EV/EBITDA.


HLA Revenue Splits

HLA Revenue Splits Notes

Source: HLA company filings
​Healthia are typically paying in the range of 3-7x EBITDA for their acquisitions, which have been conducive to their growth strategy and enhancing value for shareholders. Bad acquisitions are an investor’s pet peeve and can destroy shareholder value if they don’t compliment the core business or are done at too high a price.

Valuation + Outlook
​Market Cap
​Net Debt
​Enterprise Value
​EBITDA
​EV/EBITDA
​Div Yield
​$212m
​$53m
​$265m
​$33.8m
7.8x
2.8%
We recently saw 1300 Smiles, which ran a similar strategy to HLA except with dental clinics, get taken over by Abano Healthcare for approximately 15.5x EV/EBITDA. At below 8x EV/EBITDA, we see significant upside in HLA and the potential for multiple expansions on the back of their aggressive acquisition strategy. Heading into a post-covid world, we expect to see a backlog of people that will be booking appointments at HLA’s clinics. We like businesses like HLA that have good earnings visibility, their clinics typically have around 85% client retention and are pretty essential services. Buying a quality business like HLA on the back of a transformative acquisition at below 8x EV/EBITDA looks cheap heading into the country reopening.

We can see HLA trading at $3+.

People Infrastructure (PPE.ASX)

​People Infrastructure Ltd is an outsourced recruitment management business dedicated to the growth of Australia’s infrastructure and construction sector. Services provided by the group include recruiting, on-boarding, contracting, rostering, timesheet management, payroll, and workplace health and safety management. The four main sectors PPE is targeting include healthcare, community services, industrial services and information technology. People Infrastructure has a track record of successfully acquiring and growing businesses through leveraging its core capabilities in the sourcing, skilling, deployment and management of workforces.
Picture

Source: PPE company filings, 2 June 2021
Reopening Tailwind

PPE was well placed heading into the lockdowns given the diversity of their clients, low client concentration and the critical nature of many of the services that their clients provide. While construction has mostly continued through lockdowns, it hasn’t been at full capacity and, as a result of labour shortages and lack of overseas workers, human capital is in high demand. When you combine these factors with easing restrictions, demand for PPE’s services could lift considerably. With healthcare making up a huge chunk of PPE’s EBITDA we can also see the pent up demand for elective surgeries being a huge driver of PPE’s business when restrictions ease. As well as this, there are huge fiscal stimulus plans in play where a lot of the money will go towards infrastructure development, another tailwind for PPE.

Acquisitions

PPE has a strong pipeline of acquisitions and is well funded to pursue them with $50-70m of available funding through debt and free cash; given their strong funding the strategy is non-dilutive to shareholders. Their past acquisitions have been earnings accretive and have expanded the industries PPE operates in. Their most recent acquisitions, Techforce Personnel and Vision Surveys, increased earnings per share by 19% and the combined deal was done on a valuation of circa 3.7x pro forma EBITDA. Their acquisition strategy opens up new regions for PPE to capitalise on and creates a much bigger addressable market for the group, as seen by their move into the healthcare recruitment space.

Picture

Source: PPE company filings, February 2021
Valuation + Outlook
​Market Cap
​Net Debt
​Enterprise Value
​EBITDA
​EV/EBITDA
​Div Yield
​$351m
​$25m
​$376m
​$38m
9.9x
2.8%
​PPE has been a consistent performer since listing in the backend of 2017; they beat their initial forecasts and have grown their earnings significantly. The company has strong cash flows and isn’t capital intensive. They are well funded to execute their acquisition strategy which, to date, has proven to be accretive to earnings growth.
Picture

Souce: PPE company filings
​PPE is currently trading at an EV/EBITDA of 10x. The company has proven they can grow through their acquisition strategy and expand their services into new industries. Heading into a post-covid environment, PPE will gain from the current labour shortages and upcoming infrastructure spending. As mentioned above, the pent up demand for elective surgeries is huge and PPE is now a top two provider of healthcare recruitment in Australia, benefiting from the demand in healthcare workers due to covid-19.
Picture

Source: PPE company filings
We see PPE as a company that is not only cheap but also well placed to benefit as the country opens back up. Our valuation for PPE is $5.

Disclaimer: Both HLA and PPE are currently held in TAMIM portfolios.

Sign Up to Our Weekly Stock Insights

* Indicates required field

Name(Required)

Categories

Popular Topics